Tokyo, Oct. 26 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059424) titled 'Development of a Novel CAR-T Therapy Targeting Translational Dysfunction in Exhausted T Cells' on Oct. 25.

Study Type: Observational

Primary Sponsor: Institute - Tohoku University

Condition: Condition - Lung Cancer Classification by malignancy - Malignancy Genomic information - NO

Objective: Narrative objectives1 - The aim of this study is to develop a novel CAR-T cell therapy that restores the antitumor activity of T cells through the regulation of protein translation, with a particular focus on tRNA modifications and ribosomal function. Basic objectives2 - Others

Eligibility: Age-lower limit - 20 years-old = 20 years at the time of presentation to our institution. No restriction on sex. Patients who have provided informed consent for sample storage and research use through either: the Department of Respiratory Medicine Biobank (Project title: Establishment of a biobank system for the preservation and management of biospecimens obtained from surgical, bronchoscopic, and fluid drainage samples for respiratory diseases), or the Tohoku University Hospital Biobank (Project title: Tohoku University Hospital Personalized Medicine Center Biobank Division).

[Healthy Volunteers] Age >= 20 years at the time of participation. No restriction on sex. No ongoing treatment for malignant or autoimmune diseases. Voluntarily provided written informed consent for participation in this study. Key exclusion criteria - [Lung Cancer Cases] Patients with malignant diseases other than lung cancer. [Healthy Volunteers] Individuals who are pregnant. Target Size - 50

Recruitment Status: Recruitment status - Preinitiation Date of protocol fixation - 2025 Year 08 Month 08 Day Date of IRB - 2025 Year 10 Month 28 Day Anticipated trial start date - 2025 Year 10 Month 28 Day Last follow-up date - 2030 Year 09 Month 30 Day

To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000067901

Disclaimer: Curated by HT Syndication.